NEW YORK (GenomeWeb News) – Healthcare supply company Broadlane will sell Cepheid’s molecular diagnostics instruments, reagents, and services to its customers, which include more than 20,000 healthcare facilities in the US, Cepheid said today.
Broadlane’s client base includes acute care hospitals, ambulatory care facilities, and physician’s offices, Cepheid said.
The agreement covers Cepheid’s GeneXpert System and Xpert tests, which includes the company’s test kit for infections caused by methicillin-resistant Staphylococcus aureus.
Cepheid pointed out that a recently released study estimates that there were nearly 95,000 cases of MRSA in the US in 2005, resulting in around 18,650 deaths.
Financial terms of the agreement were not released.